Evolus, Inc. (EOLS)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Evolus, Inc. ("Evolus" or "the Company") (NASDAQ: EOLS).  The investigation concerns whether Evolus and certain of its officers and/or directors have violated federal securities laws.


On July 6, 2020, an International Trade Commission (“ITC”) judge issued a preliminary ruling in a trade secrets action involving Evolus.  The ITC judge’s non-binding decision found that Evolus and its South Korean partner firm Daewoong Pharmaceutical had stolen trade secrets from the companies Allergan and Medytox in developing the product Jeuveau, an injectable neurotoxin medication similar to Allergan’s Botox product.  The judge recommended a 10-year ban on the importation of Jeuveau into the United States.  On this news, Evolus’s stock price fell $1.46 per share, or 27.44%, to close at $3.86 per share on July 7, 2020.


If you are aware of any facts relating to this investigation, or purchased Evolus shares,  you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.